Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.75 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.75 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.75 |
| ▸ | BRD4 | O60885 | 1/20 | 0.75 |
| ▸ | TNF | P01375 | 1/20 | 0.75 |
| ▸ | IL1B | P01584 | 1/20 | 0.75 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097880 | 1.00 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31727916 | 1.00 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL29453150 | 1.00 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19612000 | 0.92 | CRBN (0.86) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19612001 | 0.92 | CRBN (0.86) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL25036187 | 0.89 | CRBN (0.80) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL10168336 | 0.87 | CRBN (0.77) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19973047 | 0.87 | CRBN (0.77) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL25031818 | 0.87 | CRBN (0.77) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL868592 | 0.86 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-11644461-B2 | Methods for measuring small molecule affinity to cereblon | CELGENE CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210102938-A1 | METHODS FOR MEASURING SMALL MOLECULE AFFINITY TO CEREBLON | CELGENE CORPORATION (US) | 2021-04-08 | — | — | US | disclosed |
| US-10816544-B2 | Methods for measuring small molecule affinity to cereblon | CELGENE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180224435-A1 | METHODS FOR MEASURING SMALL MOLECULE AFFINITY TO CEREBLON | CELGENE CORPORATION | 2018-08-09 | — | — | US | disclosed |
| WO-2018144832-A1 | METHODS FOR MEASURING SMALL MOLECULE AFFINITY TO CEREBLON | CELGENE CORPORATION (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | CRBN 5/4885IKZF3 1222/4885DDB1 424/4885 |
| US-10816544-B2 | Methods for measuring small molecule affinity to cereblon | CRBN, CHN2, CRKL | CRBN 1/4885IKZF3 1080/4885DDB1 1200/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | CRBN 5/4885IKZF3 1222/4885DDB1 424/4885 |
| US-20210102938-A1 | METHODS FOR MEASURING SMALL MOLECULE AFFINITY TO CEREBLON | CRBN, CHN2, CRKL | CRBN 1/4885IKZF3 1080/4885DDB1 1200/4885 |
| US-11644461-B2 | Methods for measuring small molecule affinity to cereblon | CRBN, CHN2, CRKL | CRBN 1/4885IKZF3 1080/4885DDB1 1200/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | CRBN 5/4885IKZF3 1222/4885DDB1 424/4885 |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | CRBN 5/4885IKZF3 1222/4885DDB1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.